Jenburkt Pharmaceuticals Drug Firm Launched Covid-19 Antiviral Drug Favivent

Jenburkt Pharmaceuticals Drug Firm on Friday launched antiviral drug Favipiravir under the brand name ‘Favivent’ for the treatment of mild to moderate COVID-19 symptoms at a price of Rs 39 per tablet.

The tablet will be available in 200 mg strength in the form of a strip of 10 tablets.

The drug will be manufactured at a pharmaceutical plant in Telangana with the highest safety and manufacturing protocols in place.

Pharma company Brinton Pharmaceuticals will be selling Favipiravir under the brand name ‘Faviton’ at a maximum retail price of Rs 59 per tablet.

Pharma major Glenmark Pharmaceuticals is already selling Favipiravir under the brand name ‘FabiFlu’ at a price of Rs 75 per tablet.

Earlier this year, the Drug Controller General of India (DCGI) had approved the use of Favipiravir — an antiviral drug developed in Japan and commonly used for treating influenza — for the treatment of mild to moderate cases of COVID-19 in India.

The company hopes that the easy accessibility and affordable price point of an effective treatment such as Favivent will offer Indian citizens a timely, much-needed therapeutic solution.